The Center for Breakthrough Medicines (CBM) is a leading player in the pharmaceutical and biotechnology industry. Its primary mission is to expedite the development and manufacturing of advanced therapies, with an aim to save lives. CBM serves a broad range of clients, including pharmaceutical and biotechnology companies, by assisting them throughout the entire process of advanced therapy development. This includes research and development, manufacturing, and commercialization.

CBM operates in the global market, leveraging its wide range of services, global capabilities, and a team of skilled experts to ensure accelerated and precise progress towards the market. The company has over 20 viral vector suites and cell processing suites, 200 L GMP plasmid manufacturing, and more than 180 analytical assays. These facilities are designed to shorten the turnaround on manufacturing Adeno-Associated Viruses (AAVs), providing more flexibility to developers in producing viral vectors for clinical and commercial use.

The company's business model is based on strategic partnerships and collaborations. For instance, CBM has partnered with SK Pharmteco, Cell One Partners, Nucleus Biologics, and Stoic Bio to expand its capabilities and accelerate the commercialization of cell and gene therapies. It also offers pre-clinical packages with plasmids, cell line, and pre-clinical vector manufacturing.

In terms of revenue, CBM makes money by providing services to its clients. These services range from research and development support to manufacturing and commercialization of advanced therapies.

Keywords: Advanced Therapies, Pharmaceutical, Biotechnology, Research and Development, Manufacturing, Commercialization, Viral Vector Suites, Cell Processing Suites, Strategic Partnerships, Pre-clinical Packages.